[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Cogent Biosciences Inc (COGT)

Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,016,111
  • Shares Outstanding, K 173,525
  • Annual Sales, $ 0 K
  • Annual Income, $ -328,940 K
  • EBIT $ -389 M
  • EBITDA $ -388 M
  • 60-Month Beta 0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.55

Options Overview Details

View History
  • Implied Volatility 63.01% (+8.83%)
  • Historical Volatility 54.01%
  • IV Percentile 18%
  • IV Rank 7.13%
  • IV High 284.46% on 11/07/25
  • IV Low 46.02% on 08/25/26
  • Expected Move (DTE 20) 1.28 (3.68%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 327
  • Volume Avg (30-Day) 1,032
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 20,166
  • Open Int (30-Day) 25,822
  • Expected Range 33.40 to 35.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.57
  • Number of Estimates 5
  • High Estimate $-0.52
  • Low Estimate $-0.61
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -14.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.53 +0.41%
on 08/28/26
43.39 -20.10%
on 08/04/26
-6.00 (-14.75%)
since 07/28/26
3-Month
30.93 +12.09%
on 06/10/26
43.39 -20.10%
on 08/04/26
-0.71 (-2.01%)
since 05/28/26
52-Week
11.60 +198.88%
on 09/22/25
43.73 -20.72%
on 12/08/25
+22.59 (+187.00%)
since 08/28/25

Most Recent Stories

More News
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 ...

COGT : 34.67 (-6.52%)
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 ...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81%...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

-  JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor,...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI:...

COGT : 34.67 (-6.52%)
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS...

COGT : 34.67 (-6.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 38.48
2nd Resistance Point 37.66
1st Resistance Point 36.17
Last Price 34.67
1st Support Level 33.85
2nd Support Level 33.03
3rd Support Level 31.54

See More

52-Week High 43.73
Last Price 34.67
Fibonacci 61.8% 31.46
Fibonacci 50% 27.67
Fibonacci 38.2% 23.87
52-Week Low 11.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.